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Abstract 
Small cell lung cancer (SCLC) is an aggressive cancer often diagnosed 
after it has metastasized. Despite the need to better understand this disease, 
SCLC remains poorly characterized at the molecular and genomic levels. Using a 
genetically-engineered mouse model of SCLC driven by conditional deletion of 
Trp53 and Rb1 in the lung, we identified several frequent, high-magnitude focal 
DNA copy number alterations in SCLC. We uncovered amplification of a novel, 
oncogenic transcription factor, Nuclear Factor I/B (Nfib) in the mouse SCLC 
model and in human SCLC. Functional studies indicate that NFIB regulates cell 
viability and proliferation during transformation.  
 
Introduction 
Small cell lung cancer (SCLC) is a highly lethal form of cancer that comprises 
approximately 20% of all lung cancer cases (Wistuba et al. 2001; Meuwissen and Berns 
2005). Unfortunately, SCLC is frequently diagnosed only after metastatic spread of the 
disease, and presently only 5% of patients survive beyond five years after diagnosis 
(Worden and Kalemkerian 2000; Cooper and Spiro 2006). Some insight has been 
gained as to the underlying mechanisms of this aggressive disease, including the 
identification of loss-of-function mutations in the tumor suppressor genes Trp53 (Yokota 
et al. 1987; Takahashi et al. 1989; Takahashi et al. 1991) and RB1 (Harbour et al. 1988; 
Yokota et al. 1988), which are observed in 75% and 90% of SCLC cases, respectively 
(Wistuba et al. 2001; Meuwissen and Berns 2005). In addition, MYC family members 
(C-MYC, L-MYC, and N-MYC) are frequently amplified in SCLC (Nau et al. 1985; 
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Meuwissen and Berns 2005). However, very little is known about other functionally 
relevant alterations in SCLC, and a more complete understanding of the disease is 
required to allow the development of new targeted treatments.  
Whole-genome profiling has been utilized to gain information about copy number 
alterations, point mutations, and translocations in tumors (Campbell et al. 2008; Ley et 
al. 2008; Mardis et al. 2009). One recent examination of thirty-three primary SCLC 
tumors and thirteen SCLC cell lines identified MYC family amplifications in 82% of 
tumors and 62% of cell lines (Voortman et al. 2010). Another study identified 22,000 
point mutations in a SCLC cell line, the majority of which were G-T transversions, a 
hallmark of carcinogens present in tobacco smoke (Toyooka et al. 2003; Lewis and 
Parry 2004; Pleasance et al. 2010). In other cancer types, comparative studies utilizing 
mouse models have aided in narrowing lists of candidate genes (Kim et al. 2006; 
Zender et al. 2006; Zender et al. 2008). Thus, we analyzed the genomic alterations that 
occur during tumor progression in a mouse model of SCLC to identify oncogenes in this 
cancer type. 
 
Results and Discussion 
Genetically-engineered mouse model of metastatic SCLC 
Berns and colleagues have developed a mouse model of SCLC (mSCLC) that 
involves the inactivation of the Trp53 and Rb1 tumor suppressor genes using 
conditional (“floxed”) alleles in p53fl/fl;Rbfl/fl mice (Jonkers et al. 2001; Vooijs et al. 2002; 
Meuwissen et al. 2003; Sage et al. 2003) (Supplemental Fig. S1). Inhalation of 
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adenovirus containing Cre recombinase results in infection of lung epithelial cells that 
develop into tumors resembling human SCLC histopathologically (Meuwissen et al. 
2003; DuPage et al. 2009) (Supplemental Fig. S1). These mice have a median survival 
time of 350 days, during which the tumors become malignant and metastatic 
(Meuwissen et al. 2003) (Supplemental Fig. S1). Similarly to human SCLC, the mSCLC 
metastasized to the thoracic lymph nodes, liver, adrenal glands, and bone (Meuwissen 
et al. 2003) (Supplemental Fig. S1). Thus, this model provided a platform with which to 
identify genetic alterations that occur during tumor progression. 
 
Identification of Nuclear Factor I/B Amplifications 
To determine the genetic alterations that occur in mSCLC, primary tumors and 
metastases were dissected and used for histology, DNA and RNA isolation, as well as 
for the derivation of cell lines (Supplemental Fig. S1). Each tumor was verified 
histopathologically to be SCLC and tumor purity was assessed by PCR for the 
recombined Trp53 and Rb1 alleles (Supplemental Fig. S1 and data not shown). The 
analysis of DNA copy number alterations in murine tumor models has previously aided 
in the identification of functionally important genes in several human cancers (Kim et al. 
2006; Zender et al. 2006; Zender et al. 2008). Thus, we analyzed mSCLC tumors and 
metastases using next generation sequencing-based DNA copy number analysis 
(Chiang et al. 2009). These data show that while the majority of the genome was 
surprisingly unaltered, several high-level focal amplifications and deletions were 
observed in tumor specimens (Fig. 1A, Supplemental Fig. S2-S4, Supplemental Table 
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1). In particular, we identified two recurrent focal amplifications centered around 82 Mb 
and 122 Mb on mouse chromosome 4 and a heterozygous deletion spanning from 
approximately 148.5 Mb to the end of chromosome 4 (Fig. 1B). Although one of the 
focal amplifications on chromosome 4 contained a known proto-oncogene involved in 
SCLC, L-myc (Mycl1) (Nau et al. 1985), the other focal amplification contained no genes 
previously implicated in this disease (Fig. 1C, Supplemental Fig. S3). To identify the 
relevant targets within the amplified region, the amplification breakpoints were mapped 
using statistical changepoint analysis of the normalized copy number ratios (Chiang et 
al. 2009). Nuclear Factor I/B (Nfib) was the only gene within this region amplified in 
each of the samples (Fig. 1C). Further, Nfib is located at the apex of the amplified peak 
in tumors and tumor-derived cell lines (Supplemental Fig. S2). Thus, Nfib represents a 
newly identified amplified gene in SCLC. 
 Nuclear Factor I/B (Nfib) is a CCAAT-box-binding transcription factor that 
regulates the expression of lung differentiation genes (Santoro et al. 1988; Steele-
Perkins et al. 2005). Nfib knockout mice have lung hypoproliferation and differentiation 
defects, in addition to brain defects, and die shortly after birth (Gründer et al. 2002). The 
chromosomal region containing Nfib has been reported to be frequently amplified in a 
mouse model of prostate cancer (Zhou et al. 2006) and in patients with triple negative 
breast cancer (Han et al. 2008). Based on the identification of Nfib as an amplified gene 
in SCLC and its potential importance in other prevalent tumor types, we chose to 
examine Nfib further. 
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 The DNA copy number of Nfib and the expression of Nfib mRNA was determined 
using real time PCR in a panel of 28 mSCLC-derived cell lines (Fig. 2A, B). Out of 28 
cell lines, sixteen had Nfib and six had L-myc amplifications (Fig. 2A, Supplemental Fig. 
S5). Notably, four mSCLC cell lines had amplified both Nfib and L-myc (Supplemental 
Fig. S5). mSCLC cell lines with increased Nfib copy number also expressed high levels 
of Nfib (Fig. 2B). Interestingly, two cell lines with normal Nfib copy number expressed 
high levels of Nfib mRNA suggesting that mechanisms other than genomic alteration 
may increase Nfib levels in SCLC (Fig. 2B). 
To confirm Nfib amplification in mouse tumors, we performed fluorescence in situ 
hybridization (FISH). FISH confirmed the amplification of Nfib in the lymph node 
metastasis analyzed in Figure 1 (Fig. 2C, D). Interestingly, in a primary tumor we found 
that Nfib amplification clearly correlated with a region of increased Nfib expression (Fig. 
2E, F). In normal lung, Nfib protein was localized appropriately to the nucleus of alveolar 
type II cells (Steele-Perkins et al. 2005) and was also nuclear in mSCLC. Additionally, 
Nfib protein was detected in a subset of lung neuroendocrine cells (Supplemental Fig. 
S6). Consistent with data from human tumor samples (Bhattacharjee et al. 2001), Nfib 
was not detected in lung adenomas that occasionally arise in this mouse model 
(Supplemental Fig. S7). Further, we observed that both lymph node and liver 
metastases very frequently expressed high levels of Nfib (Supplemental Fig. S7). These 
data confirm the amplification and increased expression of Nfib in mSCLC tumors and 
local and distant metastases.  
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NFIB amplifications in human SCLC 
We next examined whether NFIB is amplified and/or expressed in human SCLC. 
Copy number analysis revealed a broad region of amplification on chromosome 9p23 
encompassing 210 genes. GISTIC analysis identified approximately a 200 kb minimal 
region of amplification containing only one gene, NFIB (Beroukhim et al. 2007). In total, 
16 of 46 human SCLC cell lines had NFIB copy number gains (Fig. 3A). Interestingly, 11 
of the cell lines with NFIB amplification also had L-MYC amplification, and 15 out of the 
16 cell lines with amplification of NFIB displayed additional amplification of one of the 
MYC family members (Supplemental Fig. S5 and data not shown). Increased NFIB copy 
number was confirmed by real time PCR (Supplemental Fig. S8). Additionally, NFIB 
amplification was detected by FISH in 15% of primary human tumor samples (Fig. 3B). 
We next addressed whether NFIB protein was expressed in human SCLC tumor 
samples by performing IHC on a tissue microarray containing 68 distinct human SCLC 
samples. High level NFIB protein expression was noted in 16% of samples and the 
protein was detectable in 65% of tumors (Fig. 3C and Supplemental Fig. S9). 
Collectively, these data from both the mouse model and human patients suggest a 
potentially oncogenic role for NFIB in SCLC. 
 
NFIB controls apoptosis and viability in human SCLC 
 To determine which cellular processes are regulated by NFIB, we used RNA 
interference (RNAi) to inhibit NFIB in several human SCLC cell lines. In one adherent 
cell line (NCI-H446), which has high-level NFIB amplification and expresses very high 
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levels of NFIB, RNAi-mediated NFIB knockdown caused a dramatic increase in 
apoptosis and a corresponding decrease in proliferation (Fig. 4A, B and Supplemental 
Fig. S10). In a second SCLC cell line (NCI-H196), which lacked NFIB amplification, 
NFIB knockdown led to different outcomes depending on the shRNA used, with one 
inducing apoptosis and the other cellular senescence (Fig. 4C-E and Supplemental Fig. 
S10). In one final human SCLC cell line (NCI-H82), NFIB knockdown reduced 
proliferation (Supplemental Fig. S10). Collectively, these data suggest that NFIB 
expression is integral to human SCLC cell line viability and/or continued proliferation 
likely depending on the NFIB levels or the cellular context of each individual tumor. 
  
Nfib is an oncogene in mSCLC 
We next examined whether Nfib plays an oncogenic role in the cellular 
transformation of murine small cell lung tumors. For initial functional studies, we utilized 
mSCLC cell lines that expressed low levels of endogenous Nfib, in which we then stably 
expressed Nfib (Supplemental Fig. S11). Ectopic expression of Nfib in two independent 
mSCLC cell lines increased the number and size of anchorage-independent colonies 
compared to uninfected cells (Fig. 5A and Supplemental Fig. S11). Furthermore, cells 
over-expressing Nfib proliferated more quickly under standard culture conditions (Fig. 
5B and Supplemental Fig. S11). To assess which pathways were altered by the over-
expression of Nfib, we performed gene expression arrays and a Gene Set Enrichment 
Analysis (GSEA). Within curated gene sets, a number of cancer-related gene sets 
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correlated with over-expression of Nfib (Supplemental Fig. S12). These data support our 
hypothesis that Nuclear Factor I/B has oncogenic properties. 
We also investigated whether Nfib has oncogenic activity in a heterologous 
setting by testing whether Nfib could transform wild-type or p53-/- mouse embryonic 
fibroblasts (MEFs) (Fig. 5C-E and Supplemental Fig. S13). Expressing Nfib significantly 
increased colony formation in a low-density colony formation assay (Fig. 5C, D, and 
Supplemental Fig. S13). Additionally, while neither control nor Nfib expressing wild-type 
MEFs could grow under anchorage-independent conditions, expression of Nfib in p53-/- 
MEFs dramatically enhanced growth of anchorage-independent colonies (Fig. 5E and 
Supplemental Fig. S13). Finally, when wild-type MEFs were plated at high density to 
assay for the ability to overcome contact inhibition of growth, significantly more three-
dimensional foci formed when MEFs expressed Nfib (Supplemental Fig. S13).  
Interestingly, we observed frequent concurrent amplification and expression of 
both Nfib and L-myc (Fig. 1B, Supplemental Fig. S3 and S5). In some cell culture 
assays, including the formation of three dimensional foci of wild-type MEFs in high 
density conditions, we observed cooperativity between exogenous L-myc and Nfib, 
which was significant by the Bliss Independence test (Supplemental Fig. S13). Thus, L-
myc and Nfib may act synergistically in some settings.  
 The use of a genetically-engineered mouse model of SCLC enabled us to 
interrogate the genomic alterations that occur in SCLC. We identified several high-level 
focal amplifications and deletions and, notably, uncovered amplification of a novel 
potential proto-oncogene, Nuclear Factor I/B. This mouse model provides several 
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advantages over studying this cancer type in humans. First, the tumors are initiated by 
defined genetic events and the disease progresses in the absence of smoking 
carcinogen-induced passenger mutations and alterations. Second, a wealth of tumor 
and metastasis samples can be collected and utilized for DNA, RNA, and protein 
analyses as well as histology and cell line derivation. And third, tumors can be collected 
at different stages, with our data indicating that Nfib is highly expressed in the most 
advanced stages of mSCLC. Interestingly, the human SCLC cell lines in which we 
demonstrated that NFIB is critical for tumor maintenance were also derived from patient 
pleural effusions and a lymph node metastasis. Thus, advanced lesions still appear to 
critically depend on NFIB for cell viability. Given our success in analyzing copy number 
alterations in mSCLC, future efforts to catalogue point mutations in mSCLC, followed by 
cross-species analyses, would likely prioritize the daunting number of potentially 
meaningful mutations being identified in human SCLC (Pleasance et al. 2010). Our 
study highlights the power of rationally designed mouse models to uncover novel 
cancer-promoting alterations and uncovered an important proto-oncogenic transcription 
factors in SCLC. 
 
Materials and Methods 
Mice. p53fl/fl;Rbfl/fl and p53fl/fl;Rbfl/fl;Rosa26LSL-Luciferase/LSL-Luciferase mice have been 
described (Jonkers et al. 2001; Vooijs et al. 2002; Meuwissen et al. 2003; Sage et al. 
2003) (Rosa26LSL-Luciferase/LSL-Luciferase mice are unpublished, Erica Jackson, Tyler Jacks). 
They were infected intranasally or intratracheally with 2.5x107 or 108 PFU of adenovirus, 
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as previously described (DuPage et al. 2009). Mouse research was approved by the 
Committee for Animal Care, and conducted in compliance with the Animal Welfare Act 
Regulations and other federal statutes relating to animals and experiments involving 
animals, and adheres to the principles set forth in the Guide for the Care and Use of 
Laboratory Animals, National Research Council, 1996 (Institutional animal welfare 
assurance no. A-3125-01). 
 
Isolation of Tumor DNA and Production of Cell Lines. Primary tumors from the mouse 
model were snap frozen for DNA isolation and stored at -80°C. In addition, part of each 
tumor was kept for histology, cell line preparation, and snap frozen in RNALater 
(Ambion). To isolate DNA, tumors were digested in 800 µg/mL Proteinase K overnight at 
55°C and phenol/chloroform extracted. To dissociate tumors for cell lines, minced 
tumors were digested in HBSS (without calcium and magnesium), 1 mg/mL Collagenase 
IV (Worthington Biochemicals), and 0.025% trypsin-EDTA (Gibco) at 37°C for 30 
minutes. Following dissociation, samples were quenched in PBS with 10% FBS, 
incubated in 25 µg/mL DNase I (Sigma), centrifuged, filtered, and plated in standard 
tissue culture media (DME, 10% FBS, 1% L-glutamine and 50 units/mL Penicillin, 50 
µg/mL Streptomycin). 
 
Illumina sequencing and data analysis. Libraries for DNA copy number analysis were 
prepared from 5 µg of DNA using the Illumina Genomic DNA Sample Preparation Kit. 
Single-end 35 nucleotide reads were generated using the Illumina Genome Analyzer IIx. 
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Reads were aligned to the mm9 reference genome with MAQ and filtered for mapping 
quality greater than 30 (Supplemental Table 2). For each 100 kb genomic window, the 
number of reads aligning to that window were normalized by the total number of aligned 
reads in the sample. Copy number ratios were calculated as the number of normalized 
reads from the tumor sample, divided by the number of normalized reads from the 
reference 129/SVJ strain. Chromosomal boundaries of copy number changes were 
identified by changepoint analysis (Chiang et al. 2009). DNA copy number was 
visualized using the Broad Instituteʼs Integrated Genome Viewer 
(http://www.broadinstitute.org/igv).  
 
Human SCLC cell line copy number profiling. Affymetrix SNP 6.0 data was obtained 
from the Cancer Cell Line Encyclopedia (www.broadinstitute.org/ccle). DNA isolation 
and hybridization arrays were performed as recommended by Affymetrix. Probe 
normalization, segmentation, and copy-number profiles were determined as previously 
described (C.G.A.R.N. 2008). Significantly recurrent regions of somatic copy number 
alterations were identified using the latest GISTIC methodology as described 
(Beroukhim et al. 2007; Beroukhim et al. 2010). 
 
Immunohistochemistry. Anti-Nfib antibody (Abcam, 1: 500) was used for IHC using 
standard methods.  
 
 
Dooley 13 
References 
Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, 
Huang JH, Alexander S et al. 2007. Assessing the significance of chromosomal 
aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci 104: 
20007-20012. 
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, 
Boehm JS, Dobson J, Urashima M et al. 2010. The landscape of somatic copy-number 
alteration across human cancers. Nature 463: 899-905. 
Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, 
Bueno R, Gillette M et al. 2001. Classification of human lung carcinomas by mRNA 
expression profiling reveals distinct adenocarcinoma subclasses. PNAS 98: 13790-
13795. 
C.G.A.R.N. 2008. Comprehensive genomic characterization defines human 
glioblastoma genes and core pathways. Nature 455: 1061-1068. 
Campbell PJ, Stephens PJ, Pleasance ED, O'Meara S, Li H, Santarius T, Stebbings LA, 
Leroy C, Edkins S, Hardy C et al. 2008. Identification of somatically acquired 
rearrangements in cancer using genome-wide massively parallel paired-end 
sequencing. Nat Genet 40: 722. 
Chiang DY, Getz G, Jaffe DB, O'Kelly MJT, Zhao X, Carter SL, Russ C, Nusbaum C, 
Meyerson M, and Lander ES. 2009. High-resolution mapping of copy-number alterations 
with massively parallel sequencing. Nat Meth 6: 99-103. 
Cooper S and Spiro SG. 2006. Small cell lung cancer: Treatment review. Respirology 
11: 241-248. 
DuPage M, Dooley AL, and Jacks T. 2009. Conditional mouse lung cancer models 
using adenoviral or lentiviral delivery of Cre recombinase. Nat Protocols 4: 1064-1072. 
Gründer A, Ebel TT, Mallo M, Schwarzkopf G, Shimizu T, Sippel AE, and Schrewe H. 
2002. Nuclear factor I-B (Nfib) deficient mice have severe lung hypoplasia. Mechanisms 
of Development 112: 69-77. 
Han W, Jung E-M, Cho J, Lee JW, Hwang K-T, Yang S-J, Kang JJ, Bae J-Y, Jeon YK, 
Park I-A et al. 2008. DNA copy number alterations and expression of relevant genes in 
triple-negative breast cancer. Genes, Chromosomes and Cancer 47: 490-499. 
Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, and Kaye FJ. 1988. 
Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. 
Science 241: 353-357. 
Dooley 14 
Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, and Berns A. 
2001. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse 
model for breast cancer. Nat Genet 29: 418-425. 
Kim M, Gans JD, Nogueira C, Wang A, Paik J-H, Feng B, Brennan C, Hahn WC, 
Cordon-Cardo C, Wagner SN et al. 2006. Comparative Oncogenomics Identifies 
NEDD9 as a Melanoma Metastasis Gene. Cell 125: 1269-1281. 
Lewis PD and Parry JM. 2004. In silico p53 mutation hotspots in lung cancer. 
Carcinogenesis 25: 1099-1107. 
Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, Dooling D, Dunford-Shore 
BH, McGrath S, Hickenbotham M et al. 2008. DNA sequencing of a cytogenetically 
normal acute myeloid leukaemia genome. Nature 456: 66-72. 
Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton 
RS, Delehaunty KD, McGrath SD et al. 2009. Recurring mutations found by sequencing 
an acute myeloid leukemia genome. N Engl J Med 361: 1058-1066. 
Meuwissen R and Berns A. 2005. Mouse models for human lung cancer. Genes Dev 
19: 643-664. 
Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, and Berns A. 2003. 
Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a 
conditional mouse model. Cancer Cell 4: 181-189. 
Nau MM, Brooks BJ, Battey J, Sausville E, Gazdar AF, Kirsch IR, McBride OW, 
Bertness V, Hollis GF, and Minna JD. 1985. L-myc, a new myc-related gene amplified 
and expressed in human small cell lung cancer. Nature 318: 69-73. 
Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, Lin M-L, 
Beare D, Lau KW, Greenman C et al. 2010. A small-cell lung cancer genome with 
complex signatures of tobacco exposure. Nature 463: 184-190. 
Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, and Jacks T. 2003. Acute mutation 
of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 424: 223-228. 
Santoro C, Mermod N, Andrews PC, and Tjian R. 1988. A family of human CCAAT-box-
binding proteins active in transcription and DNA replication: cloning and expression of 
multiple cDNAs. Nature 334: 218-224. 
Schaffer BE, Park K-S, Yiu G, Conklin JF, Lin C, Burkhart DL, Karnezis AN, Sweet-
Cordero EA, and Sage J. 2010. Loss of p130 Accelerates Tumor Development in a 
Mouse Model for Human Small-Cell Lung Carcinoma. Cancer Research 70: 3877-3883. 
Dooley 15 
Steele-Perkins G, Plachez C, Butz KG, Yang G, Bachurski CJ, Kinsman SL, Litwack 
ED, Richards LJ, and Gronostajski RM. 2005. The Transcription Factor Gene Nfib Is 
Essential for both Lung Maturation and Brain Development. Mol Cell Biol 25: 685-698. 
Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, 
Gazdar AF, and Minna JD. 1989. p53: a frequent target for genetic abnormalities in lung 
cancer. Science 246: 491-494. 
Takahashi T, Takahashi T, Suzuki H, Hida T, Sekido Y, Ariyoshi Y, and Ueda R. 1991. 
The p53 gene is very frequently mutated in small-cell lung cancer with a distinct 
nucleotide substitution pattern. Oncogene 6: 1775-1778. 
Toyooka S, Tsuda T, and Gazdar AF. 2003. The TP53 gene, tobacco exposure, and 
lung cancer. Human Mutation 21: 229-239. 
Vooijs M, te Riele H, van der Valk M, and Berns A. 2002. Tumor formation in mice with 
somatic inactivation of the retinoblastoma gene in interphotoreceptor retinol binding 
protein-expressing cells. Oncogene 21: 4635-4645. 
Voortman J, Lee JH, Killian JK, Suuriniemi M, Wang Y, Lucchi M, Smith WI, Jr., Meltzer 
P, and Giaccone G. 2010. Array comparative genomic hybridization-based 
characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl 
Acad Sci 107: 13040-13045. 
Wistuba II, Gazdar AF, and Minna JD. 2001. Molecular genetics of small cell lung 
carcinoma. Semin Oncol 28: 3-13. 
Worden FP and Kalemkerian GP. 2000. Therapeutic advances in small cell lung cancer. 
Expert Opin Investig Drugs 9: 565-579. 
Yokota J, Akiyama T, Fung Y-KT, Benedict WF, Namba Y, Hanaoka M, Wada M, 
Terasaki T, Shimosato Y, Sugimura T et al. 1988. Altered expression of the 
retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene 3: 471-475. 
Yokota J, Wada M, Shimosato Y, Terada M, and Sugimura T. 1987. Loss of 
heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on 
chromosome 3 in adenocarcinoma of the lung. Proc Natl Acad Sci 84: 9252-9256. 
Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan S-T, Luk JM, 
Wigler M, Hannon GJ et al. 2006. Identification and Validation of Oncogenes in Liver 
Cancer Using an Integrative Oncogenomic Approach. Cell 125: 1253-1267. 
Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, Kubicka S, Luk 
JM, Schirmacher P et al. 2008. An oncogenomics-based in vivo RNAi screen identifies 
tumor suppressors in liver cancer. Cell 135: 852-864. 
Dooley 16 
Zhou Z, Flesken-Nikitin A, Corney DC, Wang W, Goodrich DW, Roy-Burman P, and 
Nikitin AY. 2006. Synergy of p53 and Rb Deficiency in a Conditional Mouse Model for 
Metastatic Prostate Cancer. Cancer Research 66: 7889-7898. 
 
Dooley 17 
Acknowledgments 
We would like to acknowledge D. Feldser, E. Meylan, N. Dimitrova, and T. 
Papagiannakopoulos for advice and C. Kim-Kiselak for critical reading of the 
manuscript. We thank Jacks Lab members and T. Parisi for reagents. We are indebted 
to the Koch Institute Core Facilities: D. Cook and A. Leshinsky (Biopolymers), E. Vasile 
(Microscopy), and G. Paradis (Flow Cytometry). We thank M. Luo (BioMicro Center) for 
microarray support and M. Leversha at Sloan Kettering Cancer Center Cytogenetics 
core facility for FISH. This work was supported by the Ludwig Center for Molecular 
Oncology at MIT, the Howard Hughes Medical Institute, and in part by the Cancer 
Center Support (core) grant P30-CA14051 from the National Cancer Institute. T.J. is a 
Howard Hughes Investigator, the David H. Koch Professor of Biology and a Daniel K. 
Ludwig Scholar. M.M.W was a Merck Fellow of the Damon Runyon Cancer Research 
Foundation and a Genentech Postdoctoral Fellow. D.Y.C. is supported by an Alfred P. 
Sloan Foundation Research Fellowship. 
 
Author Information 
Contributions 
A.L.D., M.M.W. and T.J. designed the experiments. A.L.D., M.M.W., T.D., S.S. 
performed the experiments. D.Y.C. analyzed the mouse copy number analysis, and 
C.W. provided bioinformatics support. S.B., N.S., J.B., L.G., and M.M. performed the 
human copy number analysis. E.S. and R.B. provided histopathological analysis and 
D.C. provided histological support. 
Dooley 18 
 
Competing financial interests 
The authors declare no competing financial interests. 
 
Corresponding author 
Correspondence to: Dr. T. Jacks, Koch Institute and Department of Biology, 
Massachusetts Institute of Technology, 77 Massachusetts Avenue, E17-517, 
Cambridge, Massachusetts, USA. E-mail: tjacks@mit.edu 
 
Figure Legends 
Figure 1. Nuclear Factor I/B is amplified in murine SCLC tumors. (A) Log2 ratio of tumor 
to somatic DNA copy number across the whole genome of a mSCLC lymph node 
metastasis cell line. The X chromosome has a copy number ratio of 2 due to the male 
reference genome while the sample was derived from a female mouse. (B) DNA copy 
number ratio of chromosome 4 of the same sample as in (A). Interestingly, the region 
between the two focal amplifications is near diploid and contains the tumor suppressor 
gene, Cdkn2a. Despite the well-known role of Cdkn2a in regulating p53 and Rb, which 
are already deleted in tumors, the fact that the copy number of this gene is kept low is 
consistent with this locus regulating other Rb family members (Schaffer et al. 2010). 
Copy number data is plotted as the tumor to somatic copy number ratio. (C) Integrated 
genome viewer (IGV) plot of the DNA copy number of position 79.5 to 84.5 Mb on 
chromosome 4. Scale bar indicates the log2 copy number ratio of tumor to somatic 
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reference sample. Dotted line indicates the boundaries of the minimally conserved 
region. T: primary lung tumor, Liv: liver metastasis, LN: lymph node metastasis, gray 
labels: tumor samples, black labels: cell lines. 
 
Figure 2. Nuclear Factor I/B is expressed in mSCLC. (A) Nfib is amplified in tumor- and 
metastasis-derived cell lines. A DNA copy number ratio greater than 1.2 was considered 
to be amplified, as determined by real time PCR on genomic DNA. (B) Cell lines with 
increased copy number of the Nfib locus also have increased expression of Nfib. (C) 
FISH analysis on a lymph node metastasis confirming known amplification of Nfib from 
copy number analysis. Inset is of a cell with amplified Nfib. (D) Matching Nfib IHC on the 
same lymph node metastasis as in (C), which has high Nfib expression. (E) FISH 
analysis of a lung tumor illustrating amplification of Nfib in a subset of tumor cells. Left 
inset illustrates a cell with normal Nfib copy number, right inset is a cell with amplified 
Nfib. (F) Matching Nfib IHC on the same lung tumor as in (E) demonstrating increased 
Nfib expression in the region with Nfib amplification. (C-F: scale bar is 20 µm, C, E: red: 
Nfib probe, green: control chromosome 4qA1 probe, blue: DAPI.)   
 
Figure 3. Nuclear Factor I/B is amplified and expressed in human small cell lung 
cancer. (A) IGV plot of 46 human SCLC cell lines from position 11.1 -17.2 Mb on human 
chromosome 9. Dotted line indicates the boundaries of the minimally conserved region. 
Scale bar indicates the log2 copy number ratio of tumor to somatic reference sample. (B) 
NFIB was amplified in human tissue samples, as detected by NFIB FISH. Top panel is a 
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representative sample with normal NFIB copy number. Bottom panel is a representative 
sample with amplified NFIB. Red: NFIB probe, green: control chromosome 9 9q12 
probe, blue: DAPI. Scale bar is 10 µm. (C) Quantification of NFIB expression in human 
SCLC tissue samples as detected by IHC for NFIB.   
 
Figure 4. NFIB knockdown induces death and reduces proliferation in human SCLC. (A) 
NFIB knockdown increases the percentage of cleaved caspase 3 (CC3) positive cells in 
the adherent cell line, NCI-H446, by FACS compared to control (Cont.) infected cells. 
(B) Quantification of BrdU incorporation by FACS following NFIB knockdown in the 
same cell line as (A). (C) NFIB shRNA1 induces apoptosis, as observed in an increase 
in the percentage of CC3 positive cells in the adherent cell line, NCI-H196, by FACS. 
(D) Reduced BrdU incorporation as detected by FACS following NFIB knockdown in the 
same cell line as (C). (E) Representative pictures of senescence-associated ß-
galactosidase staining (SA-ßgal) in an adherent cell line, NCI-H196, following control 
(left) or NFIB (right) knockdown with shRNA2. Quantification of the SA-ßgal staining is 
shown in the right panel. (** p value < 0.005, *** p value < 0.0005, compared to cont.). 
 
Figure 5. Nfib is a novel oncogene in murine SCLC. (A) Quantification of the number of 
soft agar colonies in the uninfected or stably expressing Nfib cell line. The values 
represent the mean +/- standard deviation of triplicate plates. (B) Growth curve of a 
primary tumor cell line, 3151T4, either uninfected or stably expressing Nfib. (C) Wild 
type MEFs either uninfected or infected with Nfib expressing viruses were plated at a 
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low density and assayed for colony formation. Colonies were visualized using crystal 
violet and quantified. Values represent the mean +/- standard error of the mean (SEM) 
of the total number of colonies in triplicate plates of both experiments utilizing two 
different MEF preparations. (D) p53-/- MEFs either uninfected or infected with Nfib 
expressing viruses were plated at a low density and assayed for colony formation. 
Colonies were visualized using crystal violet and quantified. Values represent the mean 
+/- SEM of the total number of colonies in triplicate plates of both experiments utilizing 
two different MEF preparations. (E) p53-/- MEFs either uninfected or infected with Nfib 
expressing viruses were plated in soft agar and assayed for anchorage-independent 
colony formation. Colonies were visualized using crystal violet and quantified. Values 
represent the mean +/- SEM of the number of colonies in nine camera views of triplicate 
plates in experiments utilizing two different MEF preparations.  (**: p value < 0.005, ***: 
p value < 0.0005).  
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Supplemental Information 
 
Supplemental Figure Legends 
Supplemental Figure 1. Tumor progression and metastasis in a mouse model of small 
cell lung cancer. (A) Schematic of the mouse model. Exon 19 and exons 2-10 are 
flanked by loxP sites (floxed) in the Rb1 and Trp53 genes (p53fl/fl;Rbfl/fl), respectively. 
Following Cre recombinase-mediated recombination, the exons are deleted. (B) An in 
situ small cell lung lesion 8 months after infection. (C) High magnification of an invasive 
tumor. At later stages, tumors disseminate within the lung to the (D) blood vessels and 
(E) lymphatic vessels, and metastasize locally to the (F) lymph nodes, and distantly to 
the (G) liver, (H) adrenal glands and (I) bone. (J) Detection of a bone metastasis using 
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luciferase imaging of a p53fl/fl;Rbfl/fl;Rosa26LSL-Luciferase/LSL-Luciferase mouse. (K) Micro-
computed tomography imaging of the bone metastasis. The bone metastasis is 
osteolytic, consistent with metastatic human SCLC. (left panel: right knee with bone 
metastasis, right panel: normal left knee.) (L) Kaplan-Meier survival curve of mice 
infected with two different titers of adenovirus expressing Cre recombinase. (squares: 
2.5x107 PFU, median latency: 475 days; diamonds: 1x108 PFU, median latency: 350 
days). (B-I): Hematoxylin and eosin stain. 
 
Supplemental Figure 2. Nfib is located at the peak of the amplification in mSCLC. (A) 
Focally amplified peak containing Nuclear Factor I/B is shown in two tumors. (B) Focally 
amplified peak containing Nuclear Factor I/B is shown in two cell lines. Copy number 
data is plotted as the tumor to somatic copy number ratio. T: primary lung tumor, Liv: 
liver metastasis, LN: lymph node metastasis, gray labels: tumor samples, black labels: 
cell lines. 
 
Supplemental Figure 3. Amplification of L-myc in murine small cell lung tumors and 
cell lines. (A) Amplification of L-myc (Mycl1) in four cell lines analyzed using Illumina 
sequencing-based DNA copy number analysis. T: primary lung tumor, Liv: liver 
metastasis, LN: lymph node metastasis. (B) Real time PCR on genomic DNA for 
amplification of the L-myc locus indicates that L-myc is amplified in tumor- and 
metastasis-derived cell lines. A DNA copy number ratio greater than 1.2 was considered 
an amplification, as determined by real time PCR on genomic DNA. (C) Real time PCR 
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indicates that cell lines that express high levels of Nfib also express high levels of L-
myc. (D) IGV display of copy number from 120-8-124.8 Mb on chromosome 4. The 
samples are organized from highest L-myc amplification to lowest. Scale bar indicates 
the log2 copy number ratio of tumor to somatic reference sample. Dotted line indicates 
the boundaries of the minimally conserved region. T: primary lung tumor, Liv: liver 
metastasis, LN: lymph node metastasis, gray labels: tumor samples, black labels: cell 
lines. 
 
Supplemental Figure 4. mSCLC samples contain focal amplifications and deletions. 
(A) IGV plot of DNA copy number changes in all samples across the genome. Samples 
are plotted as the log2 ratio of tumor to somatic copy number. Scale bar indicates the 
log2 copy number ratio of tumor to somatic reference sample. The dotted line indicates 
the boundaries of the minimally conserved region. T: primary lung tumor, Liv: liver 
metastasis, LN: lymph node metastasis, gray labels: tumor samples, black labels: cell 
lines. 
 
Supplemental Figure 5. Co-amplification of L-myc and Nfib in SCLC. (A) Number of 
mSCLC cell lines with amplifications of Nfib, L-myc or both Nfib and L-myc. A DNA copy 
number ratio greater than 1.2 was considered amplified, as determined by real time 
PCR on genomic DNA. (B) Number of human SCLC cell lines with amplifications of 
NFIB and/or L-MYC. A DNA copy number ratio greater than 1.2 was considered 
amplified, as determined by the copy number profiling.  
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Supplemental Figure 6. Nfib protein is expressed in lung neuroendocrine cells. (A) 
Percent of neuroendocrine bodies that contain Nfib-expressing cells. Lung 
neuroendocrine cells express Nfib as detected by double IHC for a neuroendocrine 
marker, calcitonin gene-related peptide (CGRP, red, cytoplasmic) and Nfib (brown, 
nuclear). (B) Representative image of a neuroendocrine body that lacks Nfib-expressing 
cells (CGRP-Nfib-). (C) Representative image of a neuroendocrine body that contains 
Nfib-expressing cells (CGRP+Nfib+). (B, C: 40X objective) 
 
Supplemental Figure 7. Nfib protein is expressed in mSCLC. (A) Nfib can be detected 
by IHC in an in situ SCLC lesion. (B) Nfib is expressed in an invasive small cell lung 
tumor. (C) Nfib is expressed in a lymph node metastasis. (D) Nfib is expressed in a liver 
metastasis. T: liver metastasis, Liv: normal liver. (E) Nfib is not expressed in adenomas 
that arise in the mouse model. A: adenoma, L: normal lung. (A, C: 20X objective, scale 
bar is 100 µm; B, D: 10X objective, scale bar is 200 µm, E: 20X objective) (F) Percent of 
lesions positive (dark gray), weak (light gray), and negative (white) for Nfib expression in 
lung tumors that are in situ, invasive (Inv.), disseminated (Dis.) as well as lymph node 
(LN) and liver metastases. 
 
Supplemental Figure 8. NFIB is amplified in human SCLC cell lines. (A) NFIB 
amplifications were confirmed by real time PCR on genomic DNA. All cell lines are NCI 
cell lines, except where otherwise noted.  
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Supplemental Figure 9. NFIB is expressed in human SCLC samples. (A) 
Representative images of human SCLC samples with negative, weak/moderate, or high 
NFIB expression as detected by IHC. NFIB protein expression was graded on a scale of 
0 (not expressed) to 3 (highly expressed). The scale bar is 200 µm.  
 
Supplemental Figure 10. NFIB knockdown in human SCLC cell lines. (A) Two hairpins 
knocked down NFIB in an adherent cell line, NCI-H446. (B) Western blot demonstrating 
NFIB knockdown in NCI-H196 using the same two hairpins as in (A). (C) NFIB 
knockdown is detected by Western blotting in NCI-H82. (D) NFIB knockdown reduces 
proliferation in NCI-H82, as assessed by BrdU incorporation detected by FACS. Values 
represent the mean +/- standard deviation of duplicate wells of a representative 
experiment. (Cont.: control GFP shRNA, Uninf.: uninfected cell line) 
 
Supplemental Figure 11. Nfib is an oncogene in mSCLC cell lines. (A) Stable 
expression of Nfib and/or L-myc in a mouse primary SCLC cell line (3151T4) with low 
endogenous expression of both Nfib and L-myc. (B) Crystal violet staining of soft agar 
colonies in the uninfected cell line or cell line stably expressing Nfib and/or L-myc. 
Images are representative of two separate experiments and visualized using crystal 
violet staining. (C) Quantification of the number of soft agar colonies in the uninfected 
cell line or cell line stably expressing Nfib, L-myc or L-myc & Nfib. The values represent 
the mean +/- standard deviation of triplicate plates. (D) Growth curve of a primary tumor 
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cell line, 3151T4, either uninfected or stably expressing Nfib, L-myc or L-myc & Nfib. (E) 
Growth curve of a primary tumor cell line, 3583T3, either uninfected or stably expressing 
Nfib, L-myc or L-myc & Nfib. (B-E: Uninfected and Nfib results are also shown in Figure 
5B) (D, E) The slope decreases from day 3 to 4 because the cells were reaching 
confluency after three days. Values represent the mean +/- standard error of the mean 
of two separate experiments, each performed in triplicate. (*: p value < 0.05, **: p value 
< 0.005). 
 
Supplemental Figure 12. Significant curated gene sets from the Gene Set Enrichment 
Analysis (GSEA). Curated gene sets of interest following expression of Nfib in mouse 
SCLC cell lines. A description of each of the gene sets is included. The values in the 
table represent the normalized enrichment score (NES). A FDR q-value less than 0.05 
was required to be significant. 
 
Supplemental Figure 13. Nfib is an oncogene in mouse embryonic fibroblasts. (A) 
Western blot demonstrating stable expression of Nfib and/or L-myc in wild type and  
p53-/- MEFs. (B) Crystal violet staining and quantification of low density colonies in wild 
type MEFs or wild type MEFs stably expressing Nfib and/or L-myc. Images are 
representative of two different MEF preparations and visualized using crystal violet 
staining. Values represent the mean +/- SEM of the total number of colonies in triplicate 
plates utilizing two different MEF preparations. (C) Crystal violet staining and 
quantification of low density colonies in p53-/- MEFs stably expressing Nfib and/or L-
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myc. Images are representative of two different MEF preparations and visualized using 
crystal violet staining. Values represent the mean +/- SEM of the total number of 
colonies in triplicate plates utilizing two different MEF preparations. (D) MEFs either 
uninfected or infected with Nfib and/or L-myc expressing viruses were plated at a high 
density and assayed for three-dimensional colony formation. Colonies were visualized 
using crystal violet and quantified. Values represent the mean +/- SEM of the total 
number of foci in triplicate plates utilizing two different MEF preparations. (E) 
Quantification of the number of soft agar colonies in the uninfected MEFs or MEFs 
stably expressing Nfib, L-myc or L-myc & Nfib. The values represent the mean +/- SEM 
of triplicate plates. (*: p value < 0.05, **: p value < 0.005, ***: p value < 0.0005). 
 
Supplemental Table 1. Copy number alterations in mSCLC tumor and cell line 
samples. An amplification has a somatic to reference copy number ratio greater than or 
equal to 1.3 and a deletion has a copy number ratio of less than or equal to 0.7. In 
addition, the X chromosome (Chr. 20) appears to be amplified (copy ratio of 2) if the 
tumor sample was derived from a female mouse because the reference genome is 
male. We have removed all amplifications occurring on Chr. 20 if this is the case. We 
have flagged all amplifications that occurred due to strain differences in the somatic and 
reference genomes (Germline CNV = “Y”).  
 
Supplemental Table 2. Read depth of Illumina sequencing of each mSCLC tumor and 
cell line sample. Samples correspond to those shown in Figure 1, where T: primary lung 
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tumor, Liv: liver metastasis, LN: lymph node metastasis, gray labels: tumor samples, 
black labels: cell lines. Total reads and confidently aligned reads (mapping quality 
greater than 30) are shown.
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Supplemental Methods 
Mouse imaging. Bioluminescence imaging was performed according to manufacturerʼs 
instructions (Xenogen). Micro-computed tomography (GE Healthcare) was performed on 
fixed specimens as previously described (Meylan et al. 2009) with a 27 µM voxel size. 
 
Identification of germline amplifications. Germline copy number variants were identified 
by first identifying regions with similar start and end positions with respect to the mouse 
reference genome, within statistical sampling error. At an average sampling density of 
~4.4 million aligned reads per sample, an average distance between reads of ~600 bp 
is expected. Thus, a window size of 12 kb (~20 adjacent reads) was used as the 
expected resolution for the boundaries of copy number variants. We also expected that 
germline copy number variants would occur in at least 25% of samples (at least 4 
samples). A simple filter was applied to identify putative germline copy number variants. 
We sorted the left coordinates for all predicted copy number segments. Clusters of left 
boundaries from 4 different tumors within 12 kb were flagged, and adjacent clusters 
within 100 kb were merged. The same procedure was performed for the right 
breakpoints. Segments with both left and right breakpoints meeting these criteria were 
flagged as potential germline copy number variants (denoted in column “B” in 
Supplementary Table 1). With these filtering criteria, 76 of the 686 predicted copy 
number segments corresponded to 14 potential germline copy number variants.  
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RNA purification, reverse transcription, and real time PCR. RNA was isolated following 
manufacturerʼs instructions for TRIzol (Invitrogen). 1.5 µg of RNA was reverse 
transcribed following manufacturerʼs instructions for High-Capacity cDNA Reverse 
Transcription (Applied Biosystems). cDNA was then diluted 1:10 for real time PCR 
reactions. Real time PCR reactions on genomic DNA were performed using 100 ng 
(mouse cell lines) or 200 ng (human cell lines) of DNA. All real time PCR reactions were 
performed using SYBR green (Applied Biosystems). Reactions were performed in 
triplicate and normalized to the levels of an internal control and analyzed using the 
comparative Ct method.  
  
Genomic DNA primers:  
Organism Name Sequence 
Mouse Nfib F 5ʼ ATTGCTTCACCCGGCGTTCTGTTT 
Mouse Nfib R 5ʼ AGGGTGCCAAGACAGGTGTGAAAT 
Mouse L-myc F 5ʼ AGACTCAGGCCTGCTC 
Mouse L-myc R 5ʼ GATTTCAAACAGCGGTAGATAG 
Mouse Chromosome 5 control F 5ʼ GAAGAAATTAGAGGGCATGCTTC 
Mouse Chromosome 5 control R 5ʼ CTTCTCCCAGTGACCTTATGTA 
Human NFIB F 5ʼ TTATTCCTCAGCGCCCATAACCCA 
Human NFIB R 5ʼ GGTGGAGAAGACAGAGACCTCTGA 
Human L-MYC F 5ʼ ACTGCACTCCCAGCCTCGAA 
Human L-MYC R 5ʼ TGAGAAGAGCCAATGCCTGACCT 
Human NUCLEOLIN F 5ʼ AAACTTTTGCGACGCGTACG 
Human NUCLEOLIN R 5ʼ GGGACTCCGACTAGGGCC 
 
cDNA primers:  
Organism Name Sequence 
Mouse Nfib F 5ʼ GGGACTAAGCCCAAGAGACC 
Mouse Nfib R 5ʼ GTCCAGTCACAAATCCTCAGC 
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Mouse L-myc F 5ʼ ACTCCTAGTCTGGAAGCCAGTAAC 
Mouse L-myc R 5ʼ ACGGTCACCACGTCAATCTCTTCA 
Mouse Gapdh F 5ʼ AGCTTGTCATCAACGGGAAG 
Mouse Gapdh R 5ʼ TTTGATGTTAGTGGGGTCTCG 
Human NFIB F 5ʼ GCCACAATGATCCTGCCAAGAA 
Human NFIB R 5ʼ GGTGGAGAAGACAGAGACCTCTGA 
Human L-MYC F 5ʼ ACTGCACTCCCAGCCTCGAA 
Human L-MYC R 5ʼ TGATGGTGACCGGCTTCCGAATAC 
Human GAPDH F 5ʼ AGCCACATCGCTCAGACAC 
Human GAPDH R 5ʼ GCCCAATACGACCAAATCC 
 
Immunohistochemistry. Slides used for the single Nfib IHC were deparaffinized, boiled 
in 10mM sodium citrate buffer pH 6 in a pressure cooker, washed in H20, and incubated 
in 3% H202 for 10 minutes. Slides were blocked for avidin and biotin (Vector 
Laboratories), blocked in 10% goat serum, and incubated overnight in 1:500 anti-NFIB 
antibody (Abcam). Slides were incubated in biotinylated secondary antibody and then in 
ABC reagent (ABC kit, Vectastain), signal was detected with a DAB peroxidase 
substrate kit (Vector Laboratories), and counterstained with hematoxylin. Double IHC 
was performed sequentially using the Autostainer 360 (Thermo Scientific). Antigen 
retrieval was performed using the Thermo Pre-treatment module. Anti-Nfib staining 
(Abcam, 1:1000) was performed first and signal was detected using DAB and was 
followed by anti-CGRP staining (Sigma, 1:5000), which was detected using Fast Red.  
 
Fluorescence In Situ Hybridization. Human tissue arrays (LC2001 and LC2082) were 
purchased from US Biomax, Inc. Human BAC clones RP11-355C15 and RP11-1107G7 
(spanning NFIB in 9p22-23), and mouse BAC clones RP23-386C23 and RP23-132D24 
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(for Nfib in 4qC3), together with proximal MMU4 reference clone RP23-458D19 were 
utilized in FISH analyses (BACPAC resources). BAC DNA was isolated by standard 
alkaline lysis and labeled with Red dUTP (NFIB, Nfib) or Green dUTP (reference probe) 
(Abbott Molecular, Inc., Des Plaines, IL) by nick translation. Human cosmid clone 
cCMP9.27, containing chromosome-specific satellite 3 repeats in 9q12, was used as 
reference on the human TMAs. Mouse reference BAC RP23-59B17 was part of a 1Mb 
clone set kindly proved by YJ Chung (Chung et al. 2004). The samples were imaged 
with an Applied Precision deconvolution microscope, using a 60X, NA 1.3 oil objective, 
and Softworx software. The acquired z-stack images (5 microns thick sample, 0.2 
micron/z section) were deconvolved, and a maximum projection was generated for each 
z-stack (Koch Institute Microscopy Core Facility).  
 
Immunoblotting. Anti-NFIB antibody (Active Motif, 1: 2000), anti-MYCL1 (Santa Cruz, 
clone C-20, 1:200), anti-Hsp90 (BD Transduction Laboratories, 1:20000) were used for 
western blotting following standard methods. 
 
Human SCLC cell line functional experiments. Human SCLC cell lines were obtained 
from ATCC. Individual clones from the TRC-Hs1.0 library were used for NFIB 
knockdown in human SCLC cell lines (shRNA #1: TRCN0000014680, 
CCGTGCTGTGTCTTATCCAAT, shRNA #2: TRCN0000014681, 
GCACGAAAGAGATCAAGATAT, Control (GFP shRNA): 
GCAAGCTGACCCTGAAGTTCA). All human cell lines were maintained in RPMI 
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supplemented with 10% FBS, 1% L-glutamine and 50 units/mL Penicillin, 50 µg/mL 
Streptomycin. Cells were infected with NFIB or control vectors, and after two days were 
selected using puromycin (Sigma). Cleaved caspase 3 (CC3) staining was performed 
according to manufacturerʼs instructions for flow cytometry staining (Cell Signaling). For 
cell cycle analysis, cells were incubated for 1 hour with BrdU prior to collection and 
stained for cell cycle analysis according to manufacturerʼs instructions for the BrdU Flow 
Kit (BD Pharmingen). p values were determined using Studentʼs T-tests. 
 
Senescence-associated ß-galactosidase staining. SA-ß-gal staining was performed as 
previously described (Dimri et al. 1995; Itahana et al. 2007) except the citric acid/sodium 
phosphate buffer was used at pH 5.5 and staining was performed overnight. The 
percent of SA-ß-gal+ cells was determined by counting the number of SA-ß-gal+ cells in 
at least 500 cells. p values were determined using Studentʼs T-tests. 
 
Nfib and L-myc overexpression. Nfib and L-myc were stably expressed in mouse cell 
lines using MSCV-Nfib-PGK-Neo and MSCV-L-myc-PGK-Puro, and selected with G418 
(Invitrogen) or Puromycin (Sigma), respectively. Mouse embryonic fibroblasts (MEFs) 
were infected with the overexpression vectors, but did not undergo selection. The 
mouse Nfib cDNA was FLAG tagged, and a Kozak sequence was added before the 
ATG in both the L-myc and Nfib expression vectors.  
Primers:  
Mouse Nfib cDNA F: 5ʼ CTAGAGTTAACATGATGGATTACAAAGACGATGACGATAAA 
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TATTCTCCCATCTGTCTC,  
Mouse Nfib cDNA R: 5ʼ TGACAAGATCTTCAGTTGCTTGTCTCCGCTT,  
Mouse L-myc cDNA F: 5ʼ ATGATCTCGAGCCACCATGGACTTCGACTCGTAT,  
Mouse L-myc cDNA R: 5ʼ TAGCACGGAATTCTTAGTAGCCACTGAGGTACGCGA 
 
Mouse SCLC cell line functional experiments. Following stable expression of Nfib, L-
myc or both L-myc & Nfib, cells were used in two assays. For soft agar colony formation 
assays, 1.5x104 cells were plated in 3 cm plates in 0.4% agarose on top of a layer of 
0.8% agarose (Seaplaque). Soft agar colony formation assays were done in triplicate 
and performed at least twice. Cultures were fed weekly and after two weeks, colonies 
were stained with 0.2% crystal violet and the number of colonies in at least 9 camera 
views per plate using a 10X objective was quantified. p values were determined using 
Studentʼs T-tests. Growth curve assays were performed in triplicate and performed 
twice. 105 cells were plated in triplicate wells in 6 well plates and the number of cells 
was counted each day for 4 days (Coulter Counter, Beckman). Graphs represent the 
mean number of cells +/- standard error of the mean (SEM) of the two experiments. 
 
MEF Transformation assays. The mouse embryonic fibroblast (MEF) experiments were 
performed using wild type and p53-/- MEFs each from two different embryos, in triplicate, 
and before passage 6. Following infection with L-myc and/or Nfib expression vectors, 
cells were used in three different assays. The low-density plating experiments were 
performed essentially as previously described (Sage et al. 2000), except colonies were 
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allowed to grow for three weeks and colonies were stained with 0.5% crystal violet in 
25% methanol. In the foci formation assay, 3.8x105 MEFs were plated in 6 cm plates 
and were performed as previously described (Sage et al. 2000) except the foci were 
stained using 0.5% crystal violet in 25% methanol after two weeks. All MEFs were 
grown in DME, 10% FBS, 1% L-glutamine and 50 units/mL Penicillin, 50 µg/mL 
Streptomycin, 1 mM sodium pyruvate (Sigma), non-essential amino acids (Sigma), 0.1 
mM ß-mercaptoethanol (Sigma). For soft agar colony formation assays, 1.5x104 cells 
were plated in 3 cm plates in 0.4% agarose on top of a layer of 0.8% agarose 
(Seaplaque). Cultures were fed weekly and after two weeks, colonies were stained with 
0.2% crystal violet and the number of colonies in at least 9 camera views per plate using 
a 10X objective was quantified. p values were determined using Studentʼs T-tests. 
 
Gene expression analysis.  
Microarray analysis. RNA was isolated with TRIzol (Invitrogen), labeled and hybridized 
to Affymetrix 430A_v2 chips according to manufacturerʼs instructions. Affymetrix data 
analysis was done using statistical tools provided by the r/Bioconductor projects 
(http://cran.r-project.org/; http://www.bioconductor.org/). Data import and quality control 
assessment was done using the packages Affy and AffyPLM and data was summarized 
and normalized using gcRMA (Bolstad et al. 2005a; Bolstad et al. 2005b). Differential 
expression analysis was carried out using limma (Smyth 2005). Prior to differential 
expression testing, the biological replicates of the different treatments of the 3583T3 
and 3151T4 cell lines were averaged and the mean values from these replicates were 
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used in limma and GSEA analysis (see below). Gene expression data was deposited in 
Gene Expression Omnibus (GSE29533).  
Gene Set Enrichment Analysis (GSEA). GSEA (http://www.broad.mit.edu/gsea/) was 
used to examine the distribution of groups of manually curated gene sets 
(http://www.broadinstitute.org/gsea/msigdb/genesets.jsp?collection=C2) within genes 
rank-ordered based on differential expression between the treatment classes. All the 
files required for these analyses and the results are available here 
(http://luria.mit.edu/caw_web/Dooley_Supplemental/MsigDB_v3/). 
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